{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Guo H"],"funding":["National Natural Science Foundation of China","National Natural Science Foundation of China (National Science Foundation of China)"],"pagination":["1172-1185"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8093297"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["18(5)"],"pubmed_abstract":["Haploidentical stem cell transplantation (haplo-SCT) achieves superior or at least comparable clinical outcomes to HLA-matched sibling donor transplantation (MSDT) in treating hematological malignancies. To define the underlying regulatory dynamics, we analyzed time courses of leukemia burden and immune abundance of haplo-SCT or MSDT from multiple dimension. First, we employed two nonirradiated leukemia mouse models which carried human AML-ETO or MLL-AF9 fusion gene to establish haplo-identical and major histocompatibility (MHC)-matched transplantation models and investigated the immune cell dynamic response during leukemia development in vivo. We found that haplo-matching the MHCs of leukemia cells with recipient mouse T cells prolonged leukemic mice survival and reduced leukemia burden. "],"journal":["Cellular & molecular immunology"],"pubmed_title":["Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation."],"pmcid":["PMC8093297"],"funding_grant_id":["81621001"],"pubmed_authors":["Chang YJ","Wang FR","Sun YQ","Xu LP","Chen H","Wang M","Zhang XH","Tang FF","Huang XJ","Hong Y","Guo H","Wei-Han","Yan CH","Chen YH","Mo XD","Liu KY","Wang Y"],"additional_accession":[]},"is_claimable":false,"name":"Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation.","description":"Haploidentical stem cell transplantation (haplo-SCT) achieves superior or at least comparable clinical outcomes to HLA-matched sibling donor transplantation (MSDT) in treating hematological malignancies. To define the underlying regulatory dynamics, we analyzed time courses of leukemia burden and immune abundance of haplo-SCT or MSDT from multiple dimension. First, we employed two nonirradiated leukemia mouse models which carried human AML-ETO or MLL-AF9 fusion gene to establish haplo-identical and major histocompatibility (MHC)-matched transplantation models and investigated the immune cell dynamic response during leukemia development in vivo. We found that haplo-matching the MHCs of leukemia cells with recipient mouse T cells prolonged leukemic mice survival and reduced leukemia burden. ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 May","modification":"2025-04-04T10:15:49.855Z","creation":"2025-04-04T10:15:49.855Z"},"accession":"S-EPMC8093297","cross_references":{"pubmed":["33408344"],"doi":["10.1038/s41423-020-00597-1"]}}